IN THE CLAIMS

Although not amended, the pending claims are reproduced below for the Examiner's convenience.

- 1. (Previously Presented): A method for softening expression lines on a face and/or forehead in need thereof, comprising topically applying a composition to one or more zones of the face or forehead marked with expression lines a composition comprising at least one compound selected from the group consisting of adenosine and adenosine analogues and a physiologically acceptable medium.
- 2. (Original) The method according to Claim 1, wherein said composition comprises an adenosine analogue selected from the group consisting of: agonists of adenosine receptors, compounds increasing intra- or extra-cellular adenosine levels, and mixtures thereof.
- 3. (Previously Presented): The method according to Claim 1, wherein said composition comprises at least one adenosine analogue selected from the group consisting of: 2'-deoxyadenosine; 2',3'-isopropylidene adenosine; toyocamycin; 1-methyladenosine, N-6-methyladenosine; adenosine N-oxide; 6-methylmercaptopurine riboside; 6-chloropurine riboside; 5'-adenosine monophosphate; 5'-adenosine diphosphate and 5'-adenosine triphosphate; phenylisopropyl adenosine, 1-methylisoguanosine, N⁶-cyclohexyladenosine, N⁶-cyclopentyladenosine, 2-chloro-N6-cyclopentyladenosine, 2-chloroadenosine, N⁶-phenyladenosine, 2-phenylaminoadenosine, 5'-N-methylcarboxamido-adenosine, N⁶-phenethyladenosine, 2-p-(2-carboxyethyl)phenethyl-amino-5'-N-ethylcarboxamidoadenosine, N⁶-[2-(3,5-vethylcarboxamidoadenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, N⁶-[2-(3,5-vethylcarboxamidoadenosine, 1-vethylcarboxamidoadenosine, 1-veth

Application No. 10/701,495 Response to Office Action dated August 24, 2007

dimethoxyphenyl)-2-(2-methylphenyl)-ethyl]adenosine and metrifudil; erythro-9-(2-hydroxy-3-nonyl) adenine and iodotubercidin.

- 4. (Original) The method according to Claim 1, wherein the composition comprises 0.01% to 1% by weight of adenosine and/or adenosine analogue with respect to the total composition weight.
- 5. (Original) The method according to Claim 2, wherein the composition comprises 0.01% to 1% by weight of adenosine and/or adenosine analogue with respect to the total composition weight.
- 6. (Original) The method according to Claim 3, wherein the composition comprises 0.01% to 1% by weight of adenosine and/or adenosine analogue with respect to the total composition weight.
 - 7. (Cancelled).
 - 8. (Original) The method of Claim 1, wherein said composition comprises adenosine.
 - 9. (Original) The method of Claim 4, wherein said composition comprises adenosine.
- 10. (Original) The method according to Claim 1, comprising topically applying to the skin an amount of said composition effective to provide a relaxing effect on contractile fibroblasts.
- 11. (Original) The method according to Claim 10, wherein said composition comprises an adenosine analogue selected from the group consisting of: agonists of adenosine receptors, compounds increasing intra- or extra-cellular adenosine levels, and mixtures thereof.

- 12. (Previously Presented): The method according to Claim 10, wherein said composition comprises at least one adenosine analogue selected from the group consisting of: 2'-deoxyadenosine; 2',3'-isopropylidene adenosine toyocamycin; 1-methyladenosine, N-6-methyladenosine; adenosine N-oxide; 6-methylmercaptopurine riboside; 6-chloropurine riboside; 5'-adenosine monophosphate; 5'-adenosine diphosphate and 5'-adenosine triphosphate; phenylisopropyl adenosine, 1-methylisoguanosine, N⁶-cyclohexyladenosine, N⁶-phenyladenosine, 2-chloro-N6-cyclopentyladenosine, 2-chloroadenosine, N⁶-phenyladenosine, 2-phenylaminoadenosine, 5'-N-methylcarboxamido-adenosine, N⁶-phenethyladenosine, 2-p-(2-carboxyethyl)phenethyl-amino-5'-N-ethylcarboxamidoadenosine, N-ethylcarboxamidoadenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)-ethyl]adenosine and metrifudil; erythro-9-(2-hydroxy-3-nonyl) adenine and iodotubercidin.
- 13. (Original) The method according to Claim 10, wherein the composition comprises 0.01% to 1% by weight of adenosine and/or adenosine analogue with respect to the total composition weight.
- 14. (Original) The method according to Claim 11, wherein the composition comprises 0.01% to 1% by weight of adenosine and/or adenosine analogue with respect to the total composition weight.
- 15. (Original) The method according to Claim 12, wherein the composition comprises 0.01% to 1% by weight of adenosine and/or adenosine analogue with respect to the total composition weight.
 - 16. (Canceled).

- 17. (Original) The method of Claim 10, wherein said composition comprises adenosine.
- 18. (Original) The method of Claim 13, wherein said composition comprises adenosine.
- 19. (Original) The method of Claim 1, wherein said composition comprises adenosine and at least one adenosine analogue.
- 20. (Original) The method of Claim 10, wherein said composition comprises adenosine and at least one adenosine analogue.
- 21. (Previously Presented): The method of claim 1, comprising topically applying to the skin an effective amount of said composition to reduce laugh lines and/or reduce frown lines.
- 22. (Previously Presented): The method of claim 8, comprising topically applying to the skin an effective amount of said composition to reduce laugh lines and/or reduce frown lines.
- 23. (Previously Presented): A method for softening expression lines on a face and/or forehead in need thereof, comprising topically applying a composition to one or more zones of the face or forehead marked with expression lines a composition comprising adenosine in an amount of from 0.01% to 1% by weight with respect to the total composition and a physiologically acceptable medium.